文献速递前列腺癌

前列腺特异性膜抗原正电子发射断层扫描联合多参数磁共振成像与活检筛选前列腺癌局灶治疗患者

Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy.
PubMed 文献 · BJU Int · 2023-11-08

该回顾性多中心队列研究纳入138例根治性前列腺切除术前接受多参数磁共振成像(mpMRI)、前列腺特异性膜抗原正电子发射断层扫描(PSMA-PET)和系统活检的患者,评估PSMA-PET对常规诊断工具筛选半侧消融局灶治疗(FT)患者的附加价值。结果显示,在mpMRI联合系统活检基础上加用PSMA-PET可提高对临床显著前列腺癌(csPCa)的诊断准确度(AUC从0.79升至0.84,P<0.001),并正确识别26/46(57%)不适合半侧消融FT的患者,假阳性排除4/138(3%)。

要点

  • mpMRI联合系统活检诊断csPCa的AUC为0.79,加用PSMA-PET后升至0.84(P<0.001)。
  • PSMA-PET正确识别26/46(57%)不适合半侧消融FT的患者,假阳性排除4/138(3%)。
  • 最终病理显示46/138(33%)患者不适合半侧消融FT。

核心结论

  • 在mpMRI和系统活检的常规检查基础上加用PSMA-PET可改善半侧消融FT的患者筛选,并有助于排除更适合全腺体治疗的患者。

研究设计与样本

  • 回顾性分析多中心队列(私立与机构)中138例在2011年1月至2021年7月间接受根治性前列腺切除术前mpMRI、PSMA-PET和系统活检的患者。
  • 纳入标准为符合FT共识标准:PSA<15 ng/mL、临床/影像T分期≤T2b、国际泌尿病理学会(ISUP)分级2-3级。
  • 临床显著前列腺癌(csPCa)定义为最终组织病理学ISUP分级≥2级、包膜外侵犯>0.5 mm或精囊侵犯。
  • 在四象限前列腺模型中,通过受试者工作特征曲线和2×2列联表分析计算mpMRI、系统活检和PSMA-PET单独及联合诊断csPCa的准确度。
  • 评估各诊断工具是否正确识别适合半侧消融FT的患者。

主要发现

  • 共分析552个前列腺象限,最终组织病理学显示272个(49%)象限存在csPCa。
  • mpMRI联合系统活检诊断csPCa的曲线下面积(AUC)、敏感度、特异度、阳性预测值和阴性预测值分别为0.79、75%、83%、81%和77%。
  • 加用PSMA-PET后,上述指标分别提高至0.84、87%、80%、81%和86%(P<0.001)。
  • 最终组织病理学显示46/138例患者(33%)不适合半侧消融FT。
  • 加用PSMA-PET正确识别26/46例(57%)不适合的患者,并导致4/138例(3%)假阳性排除。

关键数值与推荐

  • FT共识标准:PSA<15 ng/mL、临床/影像T分期≤T2b、ISUP分级2-3级。
  • csPCa定义:ISUP分级≥2级、包膜外侵犯>0.5 mm或精囊侵犯。

临床怎么用

  • 作者认为,在mpMRI和系统活检的常规检查基础上加用PSMA-PET可改善半侧消融FT的筛选,并指导排除更适合全腺体治疗的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the additional value of prostate-specific membrane antigen positron emission tomography (PSMA-PET) to conventional diagnostic tools to select patients for hemi-ablative focal therapy (FT). PATIENTS AND METHODS: We performed a retrospective analysis on a multicentre cohort (private and institutional) of 138 patients who underwent multiparametric magnetic resonance imaging (mpMRI), PSMA-PET, and systematic biopsies prior to radical prostatectomy between January 2011 and July 2021. Patients were eligible when they met the consensus criteria for FT: PSA <15 ng/mL, clinical/radiological T stage ≤T2b, and International Society of Urological Pathology (ISUP) grade 2-3. Clinically significant prostate cancer (csPCa) was defined as ISUP grade ≥2, extracapsular extension >0.5 mm or seminal vesicle involvement at final histopathology. The diagnostic accuracy of mpMRI, systematic biopsies and PSMA-PET for csPCa (separate and combined) was calculated within a four-quadrant prostate model by receiver-operating characteristic and 2 × 2 contingency analysis. Additionally, we assessed whether the diagnostic tools correctly identified patients suitable for hemi-ablative FT. RESULTS: In total 552 prostate quadrants were analysed and 272 (49%) contained csPCa on final histopathology. The area under the curve, sensitivity, specificity, positive predictive value and negative predictive value for csPCa were 0.79, 75%, 83%, 81% and 77%, respectively, for combined mpMRI and systematic biopsies, and improved after addition of PSMA-PET to 0.84, 87%, 80%, 81% and 86%, respectively (P < 0.001). On final histopathology 46/138 patients (33%) were not suitable for hemi-ablative FT. Addition of PSMA-PET correctly identified 26/46 (57%) non-suitable patients and resulted in 4/138 (3%) false-positive exclusions. CONCLUSIONS: Addition of PSMA-PET to the conventional work-up by mpMRI and systematic biopsies could improve selection for hemi-ablative FT and guide exclusion of patients for whom whole-gland treatments might be a more suitable treatment option.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Geboers B, Meijer D, Counter W, et al. Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy. BJU Int. 2023. PMID: 37858931. doi:10.1111/bju.16207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。